A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).
Harding J, Abou-Alfa G, Shi Y, Whang-Peng J, Yuen M, Saif W, Tian A, Gu S, Lam W, Liu S, Cheng Y, Chu E, Yen Y. A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2020, 38: tps601-tps601. DOI: 10.1200/jco.2020.38.4_suppl.tps601.Peer-Reviewed Original ResearchProgression-free survivalHepatocellular carcinomaPrimary endpointControl armFirst-line systemic treatment optionMedian progression-free survivalTreatment-related adverse eventsCTCAE version 4.0Prior systemic therapyChronic HBV infectionDisease control rateECOG performance statusObjective response ratePlacebo-controlled studySystemic treatment optionsPhase 2 studyRate of gradeKey eligibility criteriaAdvanced hepatocellular carcinomaPotential clinical benefitTyrosine kinase inhibitorsActivation/proliferationQuality of lifeTraditional Chinese medicineAdvanced disease